Sales of Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab) have been exceedingly low.
Source: Drug Industry Daily
Sales of Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab) have been exceedingly low.
Source: Drug Industry Daily